What's new? Log in Free sign up

Nurix Therapeutics (NRIX) News and press releases

Company Profile

News

From Benzinga Pro

Expert Ratings for Nurix Therapeutics

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Nurix Therapeutics, Maintains $53 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Robert Burns reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $53 price target.

Gilead Exercises First License Option Under Agreement With Nurix Therapeutics

Biotech, Large Cap, News, Health Care, Contracts, Small Cap, Movers, Trading Ideas, General

Gilead Exercises Option To License Nurix's IRAK4 Targeted Protein Degrader Development Candidate, NX-0479; Nurix To Receive A $20M Option Fee

News, Contracts

-- IRAK4 Program Represents the First of Up to Five Degrader Programs Within the 2019 Discovery Collaboration Agreement -- -- Nurix to Receive a $20 Million Option Fee -- FOSTER CITY, Calif. and SAN

Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Barclays Initiates Coverage On Nurix Therapeutics with Overweight Rating, Announces Price Target of $20

News, Price Target, Initiation, Analyst Ratings

Barclays analyst Peter Lawson initiates coverage on Nurix Therapeutics (NASDAQ:NRIX) with a Overweight rating and announces Price Target of $20.

Analyst Ratings for Nurix Therapeutics

Analyst Ratings

Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Oppenheimer Initiates Coverage On Nurix Therapeutics with Outperform Rating, Announces Price Target of $25

News, Price Target, Initiation, Analyst Ratings

Oppenheimer analyst Mark Breidenbach initiates coverage on Nurix Therapeutics (NASDAQ:NRIX) with a Outperform rating and announces Price Target of $25.

Nurix Therapeutics's Return On Capital Employed Overview

Stifel Maintains Buy on Nurix Therapeutics, Lowers Price Target to $31

News, Price Target, Analyst Ratings

Stifel analyst Stephen Willey maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and lowers the price target from $37 to $31.

JP Morgan Maintains Overweight on Nurix Therapeutics, Lowers Price Target to $36

News, Price Target, Analyst Ratings

JP Morgan analyst Eric Joseph maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and lowers the price target from $37 to $36.

HC Wainwright & Co. Reiterates Buy on Nurix Therapeutics, Maintains $53 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Robert Burns reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $53 price target.

RBC Capital Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $30

News, Price Target, Analyst Ratings

RBC Capital analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and lowers the price target from $39 to $30.

Needham Maintains Buy on Nurix Therapeutics, Lowers Price Target to $31

News, Price Target, Analyst Ratings

Needham analyst Gil Blum maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and lowers the price target from $32 to $31.

Nurix Therapeutics Q4 EPS $(0.87) Misses $(0.79) Estimate

Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.79) by 10.13 percent. This is a 2.35 percent decrease over losses of $(0.85) per share

Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline And Outlines 2023 Strategic Priorities

Nurix leads targeted protein modulation field with its wholly owned clinical stage programs and two strategic collaborations fueled by its DELigase platform Clinical data updates planned for Nurix's two

Press releases

From Benzinga Pro

Gilead Exercises Option to License Nurix's IRAK4 Targeted Protein Degrader Development Candidate, NX-0479

-- IRAK4 Program Represents the First of Up to Five Degrader Programs Within the 2019 Discovery Collaboration Agreement -- -- Nurix to Receive a $20 Million Option Fee -- Gilead Sciences, Inc. (NASDAQ:GILD) and Nurix

Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting

News, Press Releases

SAN FRANCISCO, March 14, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with

Nurix Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

SAN FRANCISCO, March 06, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update

Earnings, Press Releases

Demonstrated NX-2127 overcomes BTK inhibitor resistance mutations and provides clinical benefit to patients with hematological malignancies Achieved significant milestones in wholly owned clinical programs and

Nurix Therapeutics to Participate in Upcoming Investor Conferences

News, Press Releases

SAN FRANCISCO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with

Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities

Nurix leads targeted protein modulation field with its wholly owned clinical stage programs and two strategic collaborations fueled by its DELigase platform Clinical data updates planned for Nurix's two first-in-class

Nurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

News, Press Releases

SAN FRANCISCO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.